Abstract: A virtual network function application is to be deployed in a multi-technology virtualization environment. The multi-technology virtualization environment comprises a plurality of virtualization technologies. The application exists in a plurality of application implementations. At least one of the virtualization technologies has a preferred one of the application implementations. The deployment comprises receiving a trigger for a deployment of the virtual network function application. In response to the trigger, information is obtained about at least one optimization objective and about resource utilization in the multi-technology virtualization environment. Based on the received information, one of the plurality of virtualization technologies is selected for said deployment. One of the application implementations is also selected, and the selected application implementation need not be the preferred application implementation for the selected virtualization technology.

Abstract: Provided are novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R11 are as described herein and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: Provided are novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R11 are as described herein and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases.

Abstract: Provided are novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R14 are as described herein and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: Provided are novel imidazopyrazine derivatives having the general formula (I), wherein R1 to R11 are as described herein and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and related diseases.

Abstract: Provided are novel imidazopyrazine derivatives having the general formula (I), wherein A and R1 to R11 are as described herein and pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: The invention encompasses a new series of antibacterial compounds, compositions containing these compounds, and methods of treating Enterobacteriaceae bacterial diseases and infections using these compounds. The compounds find application in the treatment of infection with, and disease caused by Gram-negative bacteria Enterobacteriaceae species that have developed resistance to existing antibiotics.

Abstract: The present invention relates to compounds of general formula (II), to compositions comprising these compounds and to methods of treating Enterobacteriaceae bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Enterobacteriaceae.

Abstract: A method performed in a network node for identifying UEs which are non-compliant with modified CRS operation. The network node enables CRS operation according to a first configuration for a first period. The network node analyzes Information Elements (IE) in RRC Connection Re-establishment Request messages received from UEs during the first period. The network node generates a first set containing identities of UEs whose values in reestablishmentCause IE in the RRC Connection Re-establishment Request messages received during the first period are “otherFailure”. When the first period is finished, the network node enables CRS operation according a second configuration different from the first configuration for a second period. The network node analyzes IE in RRC Reestablishment Request messages received from UEs during the second period.

Abstract: A method is disclosed for a network node of a cellular communication network adapted for application of an uplink triggered cell handover functionality. The uplink triggered cell handover functionality may comprise initiating a handover when it is determined that an uplink channel performance metric relating to a serving cell falls on a first side of (e.g. is lower than) an uplink handover threshold. The method comprises dynamically restricting application of the uplink triggered cell handover functionality based on whether a restriction criterion is met or not. The restriction criterion is based on at least one of a resource cost of the uplink triggered cell handover functionality and a performance gain of the uplink triggered cell handover functionality.

Abstract: The present invention relates to compounds of general formula (II), to compositions comprising these compounds and to methods of treating Enterobacteriaceae bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Enterobacteriaceae.

Abstract: A method is disclosed for a network node of a cellular communication network adapted for application of an uplink triggered cell handover functionality. The uplink triggered cell handover functionality may comprise initiating a handover when it is determined that an uplink channel performance metric relating to a serving cell falls on a first side of (e.g. is lower than) an uplink handover threshold. The method comprises dynamically restricting application of the uplink triggered cell handover functionality based on whether a restriction criterion is met or not. The restriction criterion is based on at least one of a resource cost of the uplink triggered cell handover functionality and a performance gain of the uplink triggered cell handover functionality.

Abstract: The present disclosure relates to methods and arrangements for dynamically configuring repeated transmission of random access response messages from an access node, wherein the random access response message is repeatedly transmitted in response to receipt of a random access request from wireless device operating in a coverage enhancement, CE, mode and wherein the random access response message is configured for repeated transmission on a downlink channel using a repetition level selected from a set of repetition levels associated with a CE level of the CE mode. The repetition level represents a predetermined number of repeated transmissions and the CE level represents a group of wireless devices with similar radio conditions.

Abstract: The present invention relates to antibiotic compounds of formula (I), to compositions containing these compounds and to methods of treating bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Gram-positive and/or Gram-negative bacteria, and in particular in the treatment of infection with, and diseases caused by, Neisseria gonorrhoeae.

Abstract: Compounds of formula (I): and pharmacologically acceptable salts and pro-drugs thereof, wherein the variables are as defined in the specification, are potassium ion channel modulators, making them particularly useful in treating and preventing conditions such as pain, lower urinary tract disorders and the like.

Abstract: Compounds of formula (I): and pharmacologically acceptable salts and pro-drugs thereof, wherein the variables are as defined in the specification, are potassium ion channel modulators, making them particularly useful in treating and preventing conditions such as pain, lower urinary tract disorders and the like.

Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Abstract: This invention provides compounds and methods for treating cancer. More particularly, the invention provides compounds that inhibit Chk-1. These compounds potentiate the action of DNA-damaging agents such as chemotherapy and radiation therapy.